Boehringer Ingelheim to seek approval for survodutide after cardiac safety success
Boehringer Ingelheim’s dual-targeting weight-loss drug, survodutide, has shown safety with respect to cardiovascular events in a Phase III trial. In…
Metabolic Disorders
-
-
EASD 2026: TRIUMPH-2 data puts retatrutide above the incretin ceiling in T2D
On 30 September, at the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD) in Milan,…
-
EASD 2026: Petrelintide pairs 10.7% weight loss with placebo-like GI tolerability
On September 30, at the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD) in Milan,…
-
EASD 2026: Regeneron’s muscle preserver shows benefit at lower doses
Regeneron Pharmaceuticals’ Phase II trial of its muscle-preservation drug for patients using glucagon-like peptide-1 receptor agonists (GLP-1RAs) has met its…
-
EASD 2026: Roche’s enicepatide shows 22.7% placebo-adjusted weight loss at 48 weeks
On 30 September, at the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD) in Milan,…
-
EASD 2026: Semaglutide shows promise in treating obesity-related heart failure
At the 2026 European Association for the Study of Diabetes (EASD) Annual Meeting, research was presented that showed encouraging results…
-
Zealand dips on Boehringer-paired obesity drug’s Phase III result
Zealand Pharma’s share price fell by 12% after its partnered obesity hopeful, survodutide, failed to impress in a Phase III…
-
EASD 2026: Oral semaglutide drives weight loss after switch from injectable GLP-1s
This year at the European Association for the Study of Diabetes (EASD) Annual Meeting, real-world data from the OCTANE study…
-
EASD 2026: Semaglutide dose escalation shows lower CV risk vs tirzepatide in diabetes
This year at the European Association for the Study of Diabetes (EASD) Annual Meeting, real-world data compared cardiovascular outcomes with…
-
Roche’s acquired GLP-1/GIP normalises blood sugar in Phase II trial
Roche’s acquired GLP-1/GIP receptor agonist, enicepatide, normalised blood sugar and reduced weight in patients with type 2 diabetes and overweight…
